Background
==========

5-Hydroxytryptamine (5-HT or serotonin) is a highly conserved monoamine, which is a major neurotransmitter in the CNS. However, 5-HT is also widely distributed throughout the periphery, with critical roles identified in cardiovascular physiology, gastrointestinal and endocrine function, the regulation of food intake and energy balance, as well as pulmonary physiology \[[@B1]\]. These myriad functions are performed through at least 15 distinct receptors, grouped into seven structurally and functionally-defined families (5-HT~1~ -- 5-HT~7~ receptors, encoded by *HTR1-HTR7* genes) \[[@B2]\]. With the exception of the 5-HT~3~ receptor, which is a ligand-gated ion channel, these 5-HT receptors (5-HTRs) are members of the G protein-coupled receptor (GPCR) superfamily. Further functional diversity arises from alternative splicing (in the case of 5-HT~4~R and 5-HT~7~R), RNA editing (of the 5-HT~2C~ receptor) and both homo- and hetero-dimerization involving a variety of 5-HTRs \[[@B3],[@B4]\].

Recent genome-wide association studies (GWAS) have identified an association between single nucleotide polymorphisms (SNPs) localised to a region encompassing the *HTR4* gene and lung function, assessed by forced expiratory volume in 1 second (FEV~1~) and the ratio of FEV~1~ to forced vital capacity (FVC) \[[@B5]-[@B7]\]. Subsequent studies have demonstrated an association between this locus and chronic obstructive pulmonary disease (COPD) \[[@B8]\] and airflow obstruction in smokers \[[@B9]\].

The complexity of the serotonin receptor family is exemplified by the *HTR4* sub-family. Encoded by a complex gene spanning \~200 kb on chromosome 5q33, *HTR4* has at least 10 human splice variants identified to date. Numerous studies in recombinant systems have demonstrated that alternative splicing of the *HTR4* gene can generate receptor species with distinct pharmacological and functional profiles, although all couple positively to adenylyl cyclase, leading to cyclic AMP generation (see \[[@B10]\] for review). The majority of these splice variants share a common primary sequence for the first 358 residues, only diverging at the *C*-terminus. The exception is 5-HT~4h~R, which possesses an additional 14 residues in the second extracellular loop of the receptor and has been found in combination with the 5-HT~4b~R *C*-terminal sequence \[[@B11]\].

*HTR4* is highly expressed in the central nervous system, particularly in limbic structures, where it has been implicated in learning and memory, depression, anxiety and feeding behaviour \[[@B12]\]. Peripherally, roles for 5-HT~4~R have been identified in the gastrointestinal tract, heart, vasculature, adrenal cortex and lower urinary tract \[[@B1],[@B13]\]. Low levels of *HTR4* transcript have also been detected in lung \[[@B6],[@B14],[@B15]\] and in airway epithelial and smooth muscle cells \[[@B6],[@B16],[@B17]\].

Given the genetic association data and potential clinical significance of the *HTR4* gene in respiratory physiology and pathophysiology, we sought to i) investigate the expression profile of *HTR4* in both adult and fetal lung tissue and in lung tissue from individuals with COPD, ii) define the gene structure and iii) using the ENCODE dataset, investigate the potential functional mechanisms underlying select key *HTR4* SNPs associated with lung function. Our data demonstrate that in adult human lung tissue and isolated cells, including airway smooth muscle and bronchial epithelial cells, *HTR4* expression is very low at both protein and mRNA levels. Similar findings were observed in lung tissue isolated from COPD patients. Interestingly, we identify that 5-HT~4~R is differentially expressed across developmental stages, potentially suggesting a role for this receptor in lung development. Finally, we have identified a novel splice variant at the *N*-terminus and multiple potential regulatory mechanisms, which may underlie the observed *HTR4* SNP associations with lung function, including the alteration of transcription factor binding sites for factors linked to lung development.

Methods
=======

Immunohistochemistry (IHC)
--------------------------

Three undiseased adult lung samples and three lung samples from individuals with clinically diagnosed COPD were collected from the Nottingham Health Science Biobank (Nottingham, UK) with the required ethical approval (08/H0407/1). Twelve fetal tissue samples were collected from the Human Developmental Biology Resource (Newcastle upon Tyne and London, UK, <http://www.hdbr.org>) at diverse stages of development, specifically 19, 21 and 23 days and 10, 12, 17 and 19 weeks post-conception. Samples were consented for in accordance with national banking procedures and the UK Human Tissue Act (2004). For all samples, 4 μm whole tissue sections on glass slides were de-paraffinized in Histo-clear (National Diagnostics, Dublin, Ireland) and hydrated using decreasing concentrations of ethanol. Antigen retrieval was performed in a steamer for 20 minutes in sodium citrate buffer (pH 6.0), followed by an endogenous peroxidise block for 5 minutes (Dako, Cambs, UK). Slides were incubated with either a rabbit polyclonal anti-5-HT~4~R antibody (1:500, ab60359, Abcam, Cambridge, UK) or treated with normal rabbit IgG as a matched isotype control (Invitrogen/Life Technologies, Paisley, UK) for 1 hour at room temperature. The Dako Chemate Envision Detection Kit (Dako) with DAB chromogen was used for detection. Sections were then counterstained with Mayer's Haematoxylin (Sigma-Aldrich, Dorset, UK), dehydrated and a coverslip mounted using Vectamount (Vector Laboratories, Peterborough, UK). Human brain tissue was used as a positive control for 5-HT~4~R staining, whilst a negative control substituted the primary antibody with antibody diluent. Results were visualized using an Olympus BX14 light microscope.

Cell culture and transfection
-----------------------------

All cells were maintained at 37°C in 5% CO~2~ in a humidified incubator. Human airway smooth muscle (HASM) cells were isolated from the healthy bronchial tissue of individuals without previous asthma history undergoing surgery, and cultured as previously described \[[@B18]\]. Approval was given by the Nottingham Local Ethical Research Committee (EC00/165). Undifferentiated human bronchial epithelial cells (HBEC) (Lonza/Biologics, Slough, UK) were maintained in culture and differentiated, where relevant, as previously described \[[@B19]\]. *HTR4* mRNA expression analysis was carried out in five HASM (passage 3--5) and four HBEC (passage 3) donors, while radioligand binding experiments were performed on at least two distinct HASM and HBEC donors. CHO-K1 cells and the human bronchial epithelial cell line BEAS2B-R1 \[[@B20]\] (provided by Dr. Ray Penn, University of Maryland, Baltimore, USA) were cultured in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal calf serum (FCS; Sigma-Aldrich). CHO-K1 cells were transfected (where appropriate) in 24-well plates with a pcDNA3-HTR4a plasmid (1 μg/well) using FugeneHD transfection reagent (Promega, Southampton, UK), according to manufacturer's instructions. The pcDNA3-HTR4a plasmid was constructed by amplifying the protein-coding region of the *HTR4a* transcript from total brain RNA (Ambion/Life Technologies) and inserting this into the EcoRI site of the pcDNA3 vector. The insert in the resulting plasmid was sequence-verified as for RT-PCR products (see below).

Reverse-Transcription PCR (RT-PCR)
----------------------------------

RT-PCR used cDNA synthesised from total RNA using the Superscript First-Strand Synthesis System for RT-PCR (Invitrogen/Life Technologies), extracted from cultured cells or commercially obtained (peripheral blood mononuclear cells (PBMC; 3H Biomedical AB, Uppsala, Sweden), total lung and brain tissue (both from Ambion/Life Technologies)). Initial *HTR4* expression analysis by RT-PCR used a forward primer binding in exon 1 (primer 1F, 5′-CAGCAGAAGCTCGGCTCAG-3′) with reverse primers binding either in exon 9 (primer 9R, 5′-CTCTCATGGCTGTCTTCTGG-3′) or exon 13 (primer 13R, 5′-CAATCAGAAGCATGATTCCAG-3′), with the following cycling parameters: 35 cycles of 94°C for 1.5 minutes, 60°C for 1.5 minutes, 72°C for 1.5 minutes, followed by 72°C for 10 minutes. Expression analysis of the novel *HTR4* variant transcript used a forward primer binding in the novel exon (primer novel_F, 5′-GAATGGAGAGATCCAGATGG-3′) and primer 9R, with the following cycling protocol: 94°C for 2 minutes, then 40 cycles of 94°C for 30 seconds, 55°C for 30 seconds, 68°C for 1.5 minutes, followed by 68°C for 5 minutes. Amplicons were extracted from agarose gels using the QIAquick Gel Extraction Kit (Qiagen, Crawley, UK) and sequence verified using the BigDye Terminator v3.1 Cycle Sequencing Kit in conjunction with an ABI PRISM 310 Genetic Analyzer (Applied Biosystems/Life Technologies).

Quantitative PCR (Q-PCR)
------------------------

Expression analysis of *HTR4* was carried out in total RNA from cultured cells or commercially available total lung and brain tissue (Ambion/Life Technologies) using TaqMan methodology for real-time Q-PCR (Applied Biosystems/Life Technologies) as previously described \[[@B19]\]. In every sample, Q-PCR was carried out for *HTR4* (forward primer 5′-TCTCTTGCTTTTGCGGATCT-3′, reverse primer 5′-GCAGAGGGGTCATCTTGTTC-3′, probe 5′-CCCTTTGGTGCCATTGAGCTGGTTC-3′) and Human TFRC (CD71, transferrin receptor) Endogenous Control (Applied Biosystems/Life Technologies). Relative *HTR4* expression was calculated using the 2^-ΔΔCt^ method \[[@B21]\], corrected using the endogenous control (TFRC) and displayed relative to expression in total brain tissue.

Affymetrix U133 Plus 2 array data for human fetal lung
------------------------------------------------------

Publically available data \[[@B22],[@B23]\] were utilized to see whether *HTR4* was differentially expressed during normal human lung development. Previously, human fetal lung tissues were obtained from National Institute of Child Health and Human Development tissue databases and microarray profiled to investigate the expression spanning different gestational ages. RNA samples from 38 subjects (estimated gestational age 7--22 weeks or 53--154 days post conception) *i.e.* Pseudoglandular (gestational age, 7--16 weeks) and Canalicular (17--26 weeks) stages of development were included within the dataset. These data are available at NCBI Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo>), GSE14334. The dataset was mined for *HTR4* expression using Affymetrix probes; 216939_s\_at, 207577_at and 207578_s\_at.

Radioligand binding
-------------------

CHO-K1 cells were plated into 24-well plates and grown for 24 hours in DMEM containing 10% FCS prior to transfection. BEAS2B-R1, HBEC and HASM cells were plated into 24-well plates 24--48 hours prior to experimentation. Experiments were performed 48 hours post-transfection in HEPES-buffered saline (HBS: 20 mM HEPES, 150 mM NaCl, 4.2 mM KCl, 0.9 mM CaCl~2~, 0.5 mM MgCl~2~, 0.1% glucose, and 0.1% bovine serum albumin), as previously reported \[[@B24]\]. The reaction mixture (250 μl) containing saturating concentrations of \[^3^H\]-GR113808 (approx. 1 nM, *K*~d~ = 0.30 nM; specific activity, 83 Ci/mmol) was added to the cells and incubated for 2 hours at 4°C. Non-specific binding was defined in the presence of 5-HT (10 μM). Incubation was terminated by aspiration, followed by washing the cells with ice-cold HBS (2 × 1 ml). Cells were lysed in 0.1 M NaOH, then 10 ml of scintillation liquid (UltimaGold XR scintillation cocktail; Perkin Elmer, Bucks, UK) was added and radioactivity was measured by scintillation counting. Protein concentration was determined using a Bio-Rad protein assay (Hercules, California, USA), allowing receptor densities (in fmol/mg protein) to be determined.

5′ Rapid amplification of cDNA Ends (5′ RACE)
---------------------------------------------

Total RNA was extracted from cultured cells using the RNeasy Mini Kit (Qiagen) or obtained from commercial sources. RACE-ready cDNA was synthesised using total RNA from HASM, undifferentiated and differentiated HBEC, PBMC (3H Biomedical AB) and total lung and brain tissue (Ambion/Life Technologies) using the GeneRacer Kit (Invitrogen/Life Technologies). 5′ RACE used GeneRacer primers as well as *HTR4*-specific nested primers for amplification. PCR products generated were then cloned using the pGEM-T Easy Vector System (Promega) to identify exon structure at the 5′ end of the gene. RACE clones were sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit in conjunction with an ABI PRISM 310 Genetic Analyzer (Applied Biosystems/Life Technologies). Sequences were aligned with the 'Human Genomic + Transcript' database using the Basic Local Alignment Search Tool (BLAST) provided by the National Center for Biotechnology Information (NCBI, <http://www.ncbi.nlm.nih.gov/>). Protein structures were predicted from 5′ RACE data using online tools: the TMHMM Server v. 2.0 \[[@B25]\] and TOPO2, provided by the Sequence Analysis & Consulting Service at UCSF (<http://www.sacs.ucsf.edu/cgi-bin/open-topo2.py/>).

Bioinformatic analysis
----------------------

The *HTR4* gene was annotated with RNA sequencing, H3K27Ac histone marks, DNase I hypersensitivity, transcription factor binding (all derived from the UCSC encyclopedia of DNA elements consortium (ENCODE) database \[[@B26]\]), CpG island and placental mammal conservation tracks using the UCSC genome browser (<http://genome.ucsc.edu/>) on the Human Feb 2009 (GRCh37/hg19) assembly \[[@B27],[@B28]\]. The predicted effects of polymorphisms (in the HapMap CEU cohort, as of December 2012) in linkage disequilibrium (LD) (r^2^\>0.80) with the sentinel *HTR4* SNP (rs3995090) identified in the SpiroMeta lung function GWAS \[[@B6]\] were examined using the HaploReg database (<http://www.broadinstitute.org/mammals/haploreg/>) \[[@B29]\].

Results
=======

5-HT~4~R is expressed at low levels in adult human lung tissue
--------------------------------------------------------------

Immunohistochemistry performed with an anti-5-HT~4~R antibody in normal lung tissue from three donors identified specific staining for 5-HT~4~R in alveolar pneumocytes (Figure [1](#F1){ref-type="fig"}a-c). The staining in these cells was both cytoplasmic and membranous, which is consistent with the anticipated sub-cellular expression profile for a GPCR. Some specific 5-HT~4~R staining was also detected in bronchial epithelial cells, but substantial variation between donors was observed in this location. While strong staining was observed in the epithelial cells of donor 2 (Figure [1](#F1){ref-type="fig"}h), only weak staining was observed in the other 2 donors (Figure [1](#F1){ref-type="fig"}g and [1](#F1){ref-type="fig"}i). In addition, the strong staining in donor 2 was cytoplasmic and nuclear, with little apparent staining at the plasma membrane (Figure [1](#F1){ref-type="fig"}h). No staining was observed in any of the isotype controls (Figure [1](#F1){ref-type="fig"}d-f and [1](#F1){ref-type="fig"}j-l).

![**Immunohistochemistry of 5-HT**~**4**~**R in normal adult human lung tissue.** Low cytoplasmic and membranous expression of 5-HT~4~R was found in the pneumocytes of the alveoli in all three normal lung samples **(a**-**c)**. The epithelium showed variable staining; donor 1 had very weak cytoplasmic staining **(g)**, donor 2 had strong cytoplasmic and nuclear staining of \>50% of nuclei **(h)**, whilst donor 3 had weak staining in \<20% of epithelial cells **(i)**. All isotype controls were negative **(d**-**f** and **j**-**l)**. X40 magnification.](1465-9921-14-77-1){#F1}

5-HT~4~R is expressed at low levels in adult human lung tissue from individuals with COPD
-----------------------------------------------------------------------------------------

5-HT~4~R protein expression was analyzed by IHC in three COPD donors. Donor 1 (COPD1) was a 61 year old female, heavy smoker with moderate COPD; donor 2 (COPD2) was a 55 year old male, heavy smoker with severe COPD; donor 3 (COPD3) was a 48 year old female, heavy smoker with severe COPD. Weak 5-HT~4~R immunopositivity was found in the nuclei and cytoplasm of pneumoctyes in the alveolar regions of all three COPD samples (Figure [2](#F2){ref-type="fig"}a-c). The epithelium showed variable staining between donors: COPD1 had weak nuclear staining (Figure [2](#F2){ref-type="fig"}g), COPD2 had moderate nuclear and cytoplasmic staining (Figure [2](#F2){ref-type="fig"}h) whilst COPD3 was negative for the 5-HT~4~R protein (Figure [2](#F2){ref-type="fig"}i). All isotype controls were negative (Figure [2](#F2){ref-type="fig"}d-f and [2](#F2){ref-type="fig"}j-l).

![**Immunohistochemistry of 5-HT**~**4**~**R in COPD lung tissue.** Weak 5-HT~4~R staining was found in the nuclei and cytoplasm of pneumoctyes in the alveolar regions of all COPD samples **(a**-**c)**. In the bronchial epithelium COPD1 had weak nuclear staining **(g)**, COPD2 had moderate nuclear and cytoplasmic staining **(h)** whilst COPD3 was negative for the 5-HT~4~R protein **(i)**. All isotype controls were negative **(d**-**f** and **j**-**l)**. X40 magnification.](1465-9921-14-77-2){#F2}

5-HT~4~R is differentially expressed during fetal development at the protein and mRNA level
-------------------------------------------------------------------------------------------

Fetal tissue spanning ages 19 days-19 weeks was investigated using IHC (Figure [3](#F3){ref-type="fig"}). These data demonstrated a trend towards an increase in 5-HT~4~R protein expression spanning Embryonic (Figure [3](#F3){ref-type="fig"}a-f) to Pseudoglandular (Figure [3](#F3){ref-type="fig"}g-j) stages and a potential decrease in the Canalicular (Figure [3](#F3){ref-type="fig"}k-l) stage of development. Staining was predominantly nuclear and widespread across the airway epithelium. The gene array data demonstrated that there was a significant increase in expression levels with age during the Pseudoglandular (gestational age, 7--16 weeks) and Canalicular (17--26 weeks) stages of development, with one of the Affymetrix probes (207577_at) surviving correction for false discovery rate (Table [1](#T1){ref-type="table"}). These data suggest that an increase in 5-HT~4~R expression is a feature of lung development with a lower level of protein expression in subsequent stages, potentially reflecting the levels observed in the adult lung.

![**Immunohistochemistry of 5-HT**~**4**~**R in fetal lung tissue.** Weak staining is apparent in early Embryonic stages which increases in intensity with age leading to strong staining in the Pseudoglandular and moderate staining in the Canalicular stages. **a**-**l** represent age ordered samples of 19 days **(a**, **b)**, 21 days **(c**, **d)**, 23 days **(e**, **f)**, 10 weeks **(g**, **h)**, 12 weeks **(i**, **j)**, 17 weeks **(k)** and 19 weeks **(l)**. All isotype controls were negative (data not shown). X40 magnification.](1465-9921-14-77-3){#F3}

###### 

**Fetal lung gene array data for*HTR4*expression during Pseudoglandular and Canalicular stages of lung development**

  **Probe ID**   **AveExpr**   **t**    **P.value**   **Adj.p.val**   **Beta-coefficient**
  -------------- ------------- -------- ------------- --------------- ----------------------
  216939_s\_at   3.2999        0.9672   0.3393        0.5156          0.0009
  207577_at      3.6980        3.3242   0.0019        0.0121          0.0024
  207578_s\_at   7.0472        0.3855   0.7020        0.8160          0.0008

*AveExpr*, average expression between all samples; *t*, t-statistic describing differential expression; *P.Value*, Unadjusted p value; *adj.P.Val*, Adjusted p value controlling for false discovery rate; Beta-coefficient= log-odds ratio (corresponding to the mean change in gene expression per day during the studied period, 7--22 weeks of gestational age).

Analysis of *HTR4* gene structure in brain and *HTR4* expression profiling in airway cells by Q-PCR and radioligand binding
---------------------------------------------------------------------------------------------------------------------------

Previously described gene arrangements for *HTR4* are summarized in Figure [4](#F4){ref-type="fig"}. Transcripts a, b, i, d and g are currently reported by NCBI (December 2012); transcripts h, n, e, f and c have been described in the literature \[[@B10]\]. These data illustrate the complex splicing that exists at this gene locus, including multiple functionally relevant *C-*terminal variants, leading to alterations in cyclic AMP signalling responses \[[@B10]\]. Analysis by RT-PCR indicated expression of mRNA encoding *HTR4* in total brain tissue, but failed to detect expression in HASM, undifferentiated HBEC, PBMC or total lung tissue (data not shown). Targeted sequencing of PCR products derived from brain cDNA confirmed the presence of both variants a (accession NM_001040169.2) and b (accession NM_000870.5), distinguished by the presence of exons 9 and 13 respectively. Additionally, exon 1 was present in variant a, although this contradicts data currently reported by NCBI (Figure [5](#F5){ref-type="fig"}a). Q-PCR data indicated very low levels of mean *HTR4* mRNA expression in airway cells and tissues when compared to total brain tissue: total lung (0.26%), undifferentiated HBEC (0.05%), HASM (0.02%) and BEAS2B-R1 (0.16%) (Figure [5](#F5){ref-type="fig"}b).

![**Known*HTR4*transcript variants.** Transcripts a, b, i, d and g are currently reported by NCBI (December 2012); translational stop positions are indicated by red arrows. Transcripts h, n, e, f and c have been described in the literature \[[@B11],[@B15],[@B30]-[@B32]\].](1465-9921-14-77-4){#F4}

![**Expression profiling of*HTR4*in airway cells.** RT-PCR and sequencing confirmed expression of *HTR4* transcripts a (NM_001040169.2) and b (NM_000870.5) in total brain tissue **(a)**. Sequence encoding exon 1 was found in both transcripts, which contradicts information provided by NCBI for transcript a, however transcripts a and b were differentiated by the presence of exon 13 or 9 respectively. Q-PCR analysis **(b)** indicated highest expression in total brain tissue, but ≤0.26% relative to this in total lung tissue, HBEC, HASM and the BEAS2B-R1 cell line. Error bars indicate SEM (n ≥3). Radioligand binding experiments **(c)**, using a saturating concentration of \[^3^H\]-GR113808 (approx. 1 nM), defined 5-HT~4~R expression in CHO-K1 cells transiently transfected with pcDNA3-HTR4a, un-transfected CHO-K1 cells, HBEC, HASM and BEAS2B-R1 cells. Error bars indicate SEM (n ≥3). While the pcDNA3-HTR4a-transfected CHO-K1 cells expressed a substantial 5-HT~4~R population (approx. 460 fmol/mg protein), no other cell type expressed a significant receptor population (all ≤50 fmol/mg protein).](1465-9921-14-77-5){#F5}

In addition, radioligand binding (using the highly 5-HT~4~R-selective ligand \[^3^H\]-GR113808 \[[@B24]\]) failed to detect any significant 5-HT~4~R expression in undifferentiated HBEC (none detected; n = 3), HASM (14.1 ± 13.2 fmol/mg protein; n = 4) or BEAS2B-R1 (50.1 ± 36.6 fmol/mg protein; n = 3) cells (Figure [5](#F5){ref-type="fig"}c), in good agreement with the Q-PCR data in these cell types. In contrast, a substantial 5-HT~4~R population could be detected in CHO-K1 cells transiently transfected with pcDNA3-HTR4a (460.7 ± 69.3 fmol/mg protein; n = 4), but not in un-transfected CHO-K1 cells (8.3 ± 7.8 fmol/mg protein; n = 4). These data suggest that there is limited 5-HT~4~R expression in cultured structural cells of the adult lung, in agreement with the low levels of IHC staining for 5-HT~4~R in adult lung tissue.

5′ RACE showed variation of *HTR4* transcripts in cDNA derived from total brain tissue only; it was not possible to amplify *HTR4* transcripts from total lung tissue, HASM, HBEC (undifferentiated and differentiated) and PBMC due to the extremely low abundance. Approximately half of the analyzed clones derived from brain cDNA showed the presence of exons 1--3, although exon 1 was truncated by 41bp at the 5′ end compared to the sequence reported by NCBI (Figure [6](#F6){ref-type="fig"}a). The remaining clones possessed a novel exon of 107bp, in place of exons 1 and 2. Two consecutive RT-PCR procedures in cDNA derived from total brain, *i.e.* using the amplicon from the first as a template in a second, and confirmation by sequencing showed that the exonic structure of the novel exon-containing variant was comparable to transcript b, since sequence alignment was of good quality for consecutive exons 3, 4, 5, 7 and 9 (Figure [6](#F6){ref-type="fig"}b). However, consecutive RT-PCR procedures failed to detect this novel transcript in total lung tissue or differentiated HBEC (data not shown). Using BLAST, we found that the sequence of the novel exon aligns with a region on the same genomic contig as the *HTR4* gene (accession NG_029052.1). Using the same translational stop codon as that in transcript b, the novel transcript variant has an in-frame translational start codon (ATG) within this novel exon. The predicted protein structure of the novel transcript has an extended *N*-terminus (Figure [6](#F6){ref-type="fig"}c). Furthermore, the *N*-linked glycosylation site in the *N*-terminal region of transcript b is replaced in the novel transcript by an alternate site further upstream.

![**Analysis of*HTR4*gene structure and identification of a novel transcript variant in brain.** 5′ RACE in cDNA derived from total brain tissue indicated expression of transcripts possessing exons 1-3, and also a novel transcript in which exons 1 and 2 are replaced by an alternate exon **(a)**. The remaining sequence of the novel transcript aligns with the equivalent region of transcript b **(b)**. The predicted protein structure of this novel variant has an elongated *N*-terminus and affects the position of an *N*-linked glycosylation site in this region **(c)**.](1465-9921-14-77-6){#F6}

Analysis of HTR4 gene regulation using the ENCODE dataset
---------------------------------------------------------

Annotation of the region containing the *HTR4* gene (shown in Figure [7](#F7){ref-type="fig"}) illustrates the regulatory elements contained within this region, as predicted by the ENCODE database. There are no obvious CpG islands in this region, however substantial DNase I hypersensitivity clusters, transcription factor binding sites (identified by ChIP-seq) and H3K27Ac marks (at least in HUVEC and K562 erythroleukemia cells) are identified within the 3′ end of the *HTR4* gene. These regulatory features coincide with the region containing the variants in linkage disequlibrium (LD) (r^2^\>0.80) with the sentinel SNPs (rs3995090 and rs6889822) identified in the SpiroMeta lung function GWAS \[[@B6]\], as indicated in Figure [7](#F7){ref-type="fig"}. Less pronounced histone modification peaks, in addition to clusters of transcription factor binding and DNase I hypersensitivity sites are found towards the 5′ end of the *HTR4* gene. Using the HaploReg database focussed to one of the sentinel SNPs (rs3995090) identified in the SpiroMeta lung function GWAS \[[@B6]\], we found that this SNP was in LD (r^2^\>0.80) with an additional 28 SNPs in the 1000 Genomes dataset, which included the second sentinel SNP rs6889822 (r^2^\>0.96) (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). We identified a wide range of alterations associated with these SNPs in: i) enhancer histone marks, ii) DNase I hypersensitivity sites, iii) proteins bound and iv) regulatory motifs. Of note, three of the SNPs (rs7733088, rs4705259 and 5:147836450) in LD (r^2^\>0.80) with sentinel SNP rs3995090 significantly alter *Foxp1* binding motifs within the *HTR4* gene (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). The Fox family of transcription factors are key regulators of lung development.

![**Regulatory motifs and lung function-associated single nucleotide polymorphisms (SNPs) within the*HTR4*gene.***HTR4* annotated with RNA sequencing, H3K27Ac histone marks, DNase I hypersensitivity, transcription factor binding, CpG island and placental mammal conservation tracks (UCSC genome browser (<http://genome.ucsc.edu/>)) on the Human Feb 2009 (GRCh37/hg19) assembly. For the H3K27Ac histone marks and RNA sequence tracks, peak height is proportional to signal amplitude, with colours representing data sets in different cell backgrounds (pale blue H3K27Ac histone trace = human umbilical vein endothelial cell (HUVEC); blue/grey = K562 erythroleukemia cells). For the DNase I hypersensitivity and transcription factor binding tracks, a grey band indicates the extent of the hypersensitive region and the darkness of the band is proportional to the maximum signal strength observed in any cell line. The positions of *HTR4* variants in LD (r^2^\>0.80) with the sentinel SNP (rs3995090) identified in the SpiroMeta lung function GWAS \[[@B6]\] are also shown, with the top 2 ranking SNPs (rs3995090 and rs6889822) indicated in red.](1465-9921-14-77-7){#F7}

Discussion
==========

The translation of GWAS findings to human biology remains a challenge. In the current study we have begun to interpret our recent finding that SNPs spanning the *HTR4* gene are associated with FEV~1~ in the general population \[[@B6]\]. To this end we have extensively expression profiled the 5-HT~4~R protein and *HTR4* mRNA in human lung tissue and cells. We identified that 5-HT~4~R protein is only weakly expressed in the adult human lung, irrespective of the presence of COPD. In agreement, we identified very low levels of *HTR4* mRNA and were unable to detect a significant 5-HT~4~R population in cultured airway structural cells, including bronchial epithelial and airway smooth muscle cells. Interestingly, when we investigated 5-HT~4~R in human fetal lung tissue we identified a robust level of protein expression that appeared to be differentially regulated through lung development. In agreement, gene expression array data also showed differential *HTR4* mRNA lung expression levels across gestational stages. These data are novel and potentially suggest a role for *HTR4* in lung development. We also identified a novel *N*-terminal splice variant in brain with potential implications for 5-HT~4~R function. Finally we investigated the functional relevance of key genome-wide significant SNPs and identified multiple potential functional mechanisms *e.g.* through the alteration of developmental transcription factor binding motifs.

The very low level of *HTR4* mRNA detected in lung in the present study is consistent with a number of previous studies. For instance, Bach *et al.*\[[@B14]\] used RT-PCR to screen a variety of tissues for the expression of *HTR4a* and *HTR4b* and successfully detected both in a number of tissues (*e.g.* brain and colon). However, they only showed "barely detectable" levels of *HTR4b* (and were unable to detect *HTR4a* at all) in the lung. Medhurst *et al.*\[[@B33]\] employed a Q-PCR approach using a pan *HTR4* PCR assay and detected only very low levels of *HTR4* in lung. In contrast, Brattelid *et al.*\[[@B15]\] were able to detect both *HTR4a* and *HTR4b* in lung by RT-PCR, while Q-PCR identified *HTR4a*, *HTR4b* and *HTR4g* in the same tissue. Specifically in airway smooth muscle cells, a gene microarray study identified *HTR4g* as the only significant *HTR4* species \[[@B17]\]. Together with our findings in control and COPD subjects, the consensus from the literature would suggest that *HTR4* is expressed in adult lung, albeit at very low levels.

The majority of the literature is limited to whole lung *HTR4* expression so, in addition to human lung tissue, we chose to focus on two specific, functionally and clinically relevant primary airway cell types (cultured human bronchial epithelial cells (HBEC) and airway smooth muscle cells (HASM)), as well as the human bronchial epithelial cell line BEAS2B-R1, to investigate whether *HTR4* was enriched within a specific lung cell type. We observed similar (or even lower) levels of *HTR4* mRNA in these individual cell types as in whole lung. We also failed to detect a significant level of expression at the protein level (using \[^3^H\]-GR113808 radioligand binding) in these cells, despite successfully detecting robust 5-HT~4~R expression in pcDNA3-HTR4a-transfected CHO-K1 cells. Since \[^3^H\]-GR113808 has also previously been used to measure relatively low levels of endogenous 5-HT~4~R expression (60--223 fmol/mg protein) in human brain regions \[[@B34]\], our findings suggest that there is little enrichment of 5-HT~4~R in bronchial epithelial and airway smooth muscle cells. While the radioligand and IHC approaches to determine 5-HT~4~R protein levels in airway structural cells are in broad agreement, we cannot exclude that the lack of 5-HT~4~R protein expression observed in cultured cells is due to loss of receptor expression during passage. Bayer *et al.*\[[@B16]\] have previously identified *HTR4* expression in BEAS2B and A549 airway epithelial cell lines and in primary type II alveolar pneumocytes by RT-PCR, providing evidence for expression of *HTR4* in airway epithelial cells (albeit cell lines). Our immunohistochemical data indicate the strongest 5-HT~4~R protein expression in alveolar pneumocytes, with only weak and variable expression in bronchial epithelial cells. Taken together, these findings suggest that the main site of 5-HT~4~R expression in adult lung may be in alveolar pneumocytes.

In contrast to the adult human lung analyses, we observed clear, robust staining for 5-HT~4~R in the fetal lung tissue using immunohistochemistry. The predominantly nuclear localization of 5-HT~4~R in lung tissue suggests that the protein could have distinct roles during development, possibly beyond the scope of a classical plasma membrane-localized GPCR. Interestingly, there is a growing body of evidence for the nuclear localization and function of endogenous GPCRs in a variety of systems (see \[[@B35]\] for review). Notwithstanding the predominantly nuclear localization, our qualitative data identified a differential expression of 5-HT~4~R with gestational age, with the intensity of staining being particularly prominent in the Pseudoglandular stage of lung development. In agreement, using more quantitative mRNA data, differential expression through development was observed, with elevated *HTR4* expression across the Pseudoglandular (7--16 weeks) and Canalicular (17--26 weeks) stages. Although both immunohistochemical protein and expression array mRNA data indicate that there is differential *HTR4* gene expression during lung development, the timing of the increase in expression differs between mRNA (higher expression during the Canalicular stage) and protein (peak expression in the Pseudoglandular stage). For the gene expression microarray analysis, 26 samples in the Pseudoglandular stage (specifically 53 -- 110 days post-conception) and 12 samples in the Canalicular stage (specifically 113 -- 154 days post-conception) contributed to these analyses, whereas tissue used for immunohistochemistry included 4 samples at the Pseudoglandular stage (70 -- 94 days post-conception) and only 2 samples at the Canalicular stage (specifically 119 and 133 days post-conception). It is, therefore, possible that the differences in sample sizes and/or sample cohorts used in the two analyses could underlie this discrepancy.

Nonetheless, these lung-specific data are novel and suggest *HTR4* is likely to be of relevance to lung development. Of interest, differential 5-HT~4~R protein expression during human hypothalamus development has been described, with the appearance of 5-HT~4~R being associated with the later stages (31--32 weeks) of development \[[@B36]\]. Similarly a role for 5-HT~4~R and other serotonin receptors has also been shown in the prefrontal cortex during post-natal development, again with elevated 5-HT~4~R expression reported during the later stages \[[@B37]\]. Taken together these data suggest a role for *HTR4* in the development of multiple human tissues.

The low level of *HTR4* mRNA detected in adult lung precluded a thorough investigation of the splice variant expression profile in human airways. However, there is extensive evidence for functionally relevant *HTR4* splicing, in particular at the *C*-terminus \[[@B10]\]. In brain, we were able to successfully perform 5′ RACE, which indicated significant expression of a previously un-reported *HTR4* splice variant, arising from the replacement of exons 1 and 2 by a novel exon. The resulting variant is predicted to possess an extended *N*-terminus (14 amino acids longer than the other 5-HT~4~R isoforms) and a distinct *N-*glycosylation site (at position 2 in the novel variant, as opposed to position 7 in all other reported human 5-HT~4~R variants). Interestingly, although our findings represent the first example of variation at the *N*-terminus of the human 5-HT~4~R, several transcripts encoding different *N*-termini have been identified in mouse brain \[[@B38]\]. Sequence predictions based upon these novel transcripts indicated changes in *N*-terminal length and in some cases altered phosphorylation, acetylation and glycosylation sites \[[@B38]\], highlighting parallels with our own findings in human brain. *N*-terminal structure and in particular the *N*-glycosylation of GPCRs may influence a range of receptor functions, including the trafficking of receptors to the cell surface, ligand binding, receptor activation and down-regulation \[[@B39]\].

SNPs within *HTR4* have been associated with lung function \[[@B5],[@B6]\] and COPD/airway obstruction \[[@B8],[@B9]\] in several populations. Recently, *HTR4* SNPs have also been associated with asthma in a Korean population, with the most significant associations localized to introns within *HTR4* that were previously identified in the SpiroMeta/CHARGE lung function meta-analyses \[[@B5],[@B6],[@B40]\]. However, large scale analyses of asthma utilizing 10,365 asthma and 16,110 unaffected controls as part of the GABRIEL study did not identify an association for *HTR4* SNPs \[[@B41]\].

The functional relevance of associated *HTR4* SNPs remains to be determined, however the potential localization of the key SNPs (*i.e.* rs3995090 and rs6889822) from the SpiroMeta lung function meta-analyses to intron 6 of the gene (variant a) provided an initial focus for the current study. The ENCODE database identified a number of features within this locus (histone modifications, DNase I hypersensitivity clusters and transcription factor binding sites) consistent with a regulatory region. Interestingly, according to the HaploReg database, three of the SNPs (rs7733088, rs4705259 and 5:147836450) in LD (r^2^\>0.80) with the sentinel SNP (rs3995090) identified in the SpiroMeta lung function GWAS significantly alter Foxp1 binding motifs within *HTR4*. The Fox family of transcription factors are key regulators of lung development. In particular, the sub-family of Foxp1/2/4 is highly expressed in the developing airway epithelium, as well as in the adult lung \[[@B42]\]. Foxp1 and Foxp2 co-operatively regulate distal lung epithelial development \[[@B43]\], while Foxp1 and Foxp4 together modulate lung secretory epithelial cell fate during development and regeneration, by restricting the goblet cell differentiation program \[[@B44]\]. Given the presence of a Foxp1 binding motif within the region of *HTR4* associated with lung function, it is tempting to speculate that Foxp1 binding in this locus might be important in regulating *HTR4* during lung development.

Influences on airway growth during development can have long-term physiological effects within the lung \[[@B45]\]. Our data suggest that *HTR4* is differentially expressed in the developing lung. When taken together with the finding that SNPs in LD with those associated with lung function alter transcription factor binding sites for factors known to be involved in lung development, our results suggest that *HTR4* expression may be important for lung development. In agreement with this interpretation, it is important to note that the association between *HTR4* SNPs and lung function was apparent in children included in GWAS meta-analyses of lung function, *e.g.* in the ALSPAC (Avon Longitudinal Study of Parents and Children) and in the Raine Studies \[[@B6],[@B7]\].

It is also important to note that a role for 5-HT~4~R in post-natal lung related functions has been described including: the modulation of cytokine release in human alveolar type II cells \[[@B16]\], influencing the effect of 5-HT on cholinergic contraction in human bronchial strips \[[@B46]\] and bronchopulmonary C-fibre mediated cough and dyspnea \[[@B47]\]. Similarly, 5-HT~4~R is expressed in the pre-Bötzinger complex in the CNS, and has been demonstrated to regulate spontaneous respiratory activity \[[@B48]\].

Conclusions
===========

In summary, we have demonstrated that *HTR4* is expressed at the mRNA and protein level in adult lung tissue, albeit at a low level, using both normal and COPD lung tissue sections and cultured airway cells. The analyses of lung tissue from different fetal stages of development highlight differential expression of *HTR4* at the protein and mRNA level, suggesting a developmental role. Intriguingly, we have also identified that the key SNPs in *HTR4* associated with lung function also potentially alter binding of a series of key transcription factors of relevance for the development of multiple organs. Finally, we further characterized the gene structure of *HTR4*, identifying in brain a novel splice variant with potential functional implications. These data represent a significant advance in our knowledge of the role of *HTR4* in the lung and provide the first steps towards the translation of population-based genetic association into respiratory biology.
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